RE:New FDA Proposed Guidance on AADoubt it will have any impact on us... So far, Accelerated Approvals have been handed ou to techs with low response rates.
If Ruvidar shows a non-toxic, Complete response rate in the 40%+ range, it won't matter if the trial was single-arm, as clear efficacy will be demonstrated...
In fact, slowing TLT"s progress at that junctire would leave the FDA open to ridicule, if not lawsuits.
Big Pharma and the FDA have already been accused of slowing possible cancer cures. In this instance, the evidence would be clear.
No one at the FDA wants to confirm the worst rumours about its possible corruption in favour of Big Pharma.
So, I'm not worried.
GLTA real investors! 2023 is the Year of Ruvidar!